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Introduction
An ectopic pregnancy (EP) results from implantation outside the uterine cavity.
[1] It is an obstetric emergency. Undiagnosed it leads to rupture and haemorrhage. 
Despite the improvement in diagnostic techniques haemorrhage from EP remains 
the leading cause of pregnancy-related maternal mortality in the first trimester, 
accounting for 4% of all such deaths.[2] The recurrence rate is as high as 15%.[3,4] 
Studies in Ethiopia reported a higher incidence among 20 to 29-year-olds and 
unmarried and nulliparous women.[1,5,6] Ethiopia is among the countries with a 
high incidence with the EP being the leading cause of death in the first trimester.[7,8]
Research indicates that medical management of EP is a possible alternative to 
surgery. Methotrexate (MTX) seems to be the preferred medication. Medical 
management avoids the complications of surgery and anaesthesia and reduces 
costs.  Most of these studies were conducted in developed countries with different 
settings and practices.[9]
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Abstract
Background: Ectopic pregnancy, a pregnancy in which the embryo implants 
outside the endometrial cavity, is an important cause of maternal mortality, 
especially in developing countries. It can be managed medically using 
methotrexate. In Ethiopia, limited evidence exists regarding the treatment 
outcome of this approach.
Methods: This retrospective study was conducted based on medical records 
of ectopic pregnancies managed medically using methotrexate. The data 
of women who had unruptured ectopic pregnancy and who were managed 
medically in the study period at St. Paul’s Hospital Millennium Medical 
College were included. Data were extracted from patients’ medical records 
and analysed using SPSS software.  
Results: During the 5-year period 2015 to 2019, 81 women with unruptured 
ectopic pregnancy were managed medically using methotrexate with 93.8% 
(n=76) success. Methotrexate was administered intramuscularly to all patients 
in either single dose or multiple doses. Five out of the 81 patients underwent 
surgical intervention for either ectopic rupture or persistent ectopic mass. 
There were no fatal complications. 
Conclusion: Methotrexate is a successful and safe alternative to surgical 
management of unruptured ectopic pregnancy in our settings. It should be 
given a trial in patients who meet the selection criteria in a setting ready for 
emergency surgical intervention and blood transfusions.
Key words: Ectopic pregnancy, methotrexate, medical management, beta 
hCG, Addis Ababa.
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Medical management using MTX is being practiced 
in some referral hospitals in Ethiopia but there is no 
information on effectiveness.  Studies conducted on EP in 
in Ethiopia [1,5,6] have not addressed its surgical or medical 
management outcomes.  This study focused on treatment 
outcomes, with the hope that the results will inform 
decisions on the management of unruptured EP, as well 
as being a reference for future research.
Methodology
This retrospective study was based on medical records of 
EP patients managed medically using MTX at St. Paul’s 
Hospital Millennium Medical College from January 1st 
2015 to December 31st 2019. All patients with unruptured 
EP, who were given MTX (50mg/dose by intramuscular 
injection) as initial treatment, were included. Medical 
record numbers were extracted from the medical registry 
books in wards and emergency outpatients. The patients’ 
charts were retrieved and data were extracted, using a 
structured and pretested format, and after confirmation 
of accuracy and completeness, were analysed using SPSS 
software.
Results
Eighty-one patients had been managed using  MTX. 
The diagnosis of EP was made with trans-abdominal and 
transvaginal sonography and serum beta human chorionic 
gonadotropin (hCG). Table 1 shows that most of the 
women (60.5%) were aged 20 to 29 years, with only four 
(4.9 %) under 20 years; most were married (86%), 39% 
were nulliparous, 26.0% each were para 1 and para 2 and 
above. None had a recorded history of pelvic inflammatory 
disease.  Twelve women (14.8%) had a history of EP for 
which unilateral salpingectomy was done, and 13 (16%) 
had at least one abortion.
Three patients (3.7%) presented with abdominal pain 
only. The remainder presented with either amenorrhoea 
alone or with lower abdominal pain.  None had vaginal 
bleeding. The gestational age of the fetus was below 
eight weeks in 40.7% ( n=33) and equal or greater than 
8 weeks in 45.7% (n= 37) based on the last menstrual 
period (LMP). Eleven patients had unknown LMP dates 
but claimed to have had amenorrhoea for not more than 
two months. 
The pre-treatment serum beta hCG levels for most of 
the patients (70.4%) was below 5,000 iu, with the levels 
above 10,000 iu for 8.6%. No foetal cardiac activity was 
seen on ultrasound for all patients and the gestational sac 
(GS) diameter was below 3.5 cm for most (93.8%,). One 
patient had a GS diameter above 4 cm.
MTX was given intramuscularly to all patients in either 
a single dose (60.5%) or multiple doses if the beta hCG 
did not reduce (39.5%). Leucovorin, a drug to alleviate 
Variables n (%)
Maternal age groups 
(years)
below 20 4 (4.9)
20 – 29 49 (60.5)
30 and above 28 (34.6%)
Marital status Single 11 (14)
Married 70 (86)
Parity Nulliparous 39 (48.1)
Para 1 21 (26.0)
Para 2 or greater 21 (26.0)
Gestational age 
(weeks)
< 8 33 (40.7)
>8 37 (45.7)
Unknown 11 (13.6)
History of abortion Nil 68 (84)
1 8 (9.9)
2 2 (2.5)
3 or more 3 (3.6)
History of EP Yes 12 (14.8)
No 69 (85.2)
Presenting 
complaint
Amenorrhoea 42 (51.9)
Abdominal pain 3 (3.7)
Both 36 (44.4)
Gestational sac 
diameter
< 3.5cm 76 (93.8)
3.5 - 4cm 4 (4.9)
> 4cm 1 (1.2)
Foetal cardiac 
activity on 
ultrasound
Present 0 (0)
Absent 81 (100)
Pre-treatment 
Serum beta hCG i.u.
< 1,000 23 (28.4)
1000 - <5,000 34 (42)
5,000 - 10,000 17 (21)
>10,000 7 (8.6)
Table 1. Details of the pre-treatment patients’ information 
(N=81)
side effects of methotrexate, was given to all patients who 
had multiple doses. However, only two patients had mild 
vomiting. 
Of the 81 patients, five (6.2%) underwent surgical 
intervention (two for ectopic rupture and three for 
persistent EP).
All with successful medical treatment (93.8%) were 
discharged within ten days. The serum beta hCG levels 
at the time of discharge were below 1,500 iu for most 
(90.8%). 
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was 93.8%.[9] If selection criteria were strictly followed, 
we would have concluded that the treatment outcomes 
between single and multiple doses is comparable.[9,10,11] 
Fifty three percent of patients in the single dose regimen 
group required a second dose of MTX, a rate higher than 
reported in India and Jordan.[12,13] This was dictated by 
the unsatisfactory reduction of the serum level of beta 
hCG after the first. In this study, the failure rate was 
6.2%, similar to a meta-analysis of previous studies[9] but 
lower than reported in India.[12] For the five patients for 
whom medical management was unsuccessful, the pre-
treatment serum beta hCG levels were above 15,000 iu for 
three patients, while the GS size was above 4 cm for the 
fourth patient. The size of the ectopic mass and beta hCG 
levels were in the recommended ranges[11,15] for medical 
treatment in only one patient who underwent surgery for 
ruptured EP. 
Although such levels of serum beta hCG and the size of 
ectopic mass were reported to affect the success rate of 
medical management[10,14,15], treatment using MTX was 
given a trial in these patients, probably because four of 
them had a unilateral salpingectomy for previous EP. 
None of them required blood transfusion. It is observed 
from this study that, the earlier the gestational age, the 
lower the pre-treatment serum hCG and the smaller the 
GS diameter, the more rapid the rate of decline of the 
serum hCG and the resolution of the ectopic mass and 
therefore, the earlier the hospital discharge. So the levels 
of serum beta hCG above 10,000 iu and the ectopic 
mass size greater than 3.5 cm were the identified factors 
affecting the success rate of this treatment.
Longer hospital stays (more than 7 days for 59% of 
patients) and costs for the medication (especially for those 
who completed all four doses) and serial investigations 
were the drawback of this treatment. There was no serious 
morbidity reported and no fatalities.
Conclusion
We have confirmed that MTX in our setting is a 
successful alternative to surgical management for patients 
with unruptured EP who meet certain criteria. We expect 
success rate to be higher if strict selection of patients were 
made based on these criteria.
Although treatment was successful in many patients whose 
pre-treatment serum beta hCG levels were above 5,000 iu, 
we agree with previous studies that reported serum beta 
hCG levels to be the most important determinant for 
treatment success and recommend levels of 5,000 iu or 
below to be used as the main selection criterion. 
Our study included a small sample size and did not address 
long term outcomes of this treatment option. Therefore, 
we recommend that further research with larger numbers 
is undertaken with attention to long term outcomes. Early 
Variables n (%)
MTX dose protocol 1 dose 23 (28.4)
2 doses 26 (32.1)
3 doses 8 (9.9)
4 doses 24 (29.6)
Leucovorin Given 31 (38.2)
Not given 50 (61.8)
Side effects Yes 02 (2.6)
No 74 (97.4)
Treatment outcome Discharged 76 (93.8)
Ruptured 2 (2.5)
Persistent 3 (93.7)
Period of hospital stay 7 days or less 31 (40.8)
>7 days 45 (59.2)
Serum Beta hCG on 
discharge
< 1,000 61 (80.3)
1,000 - <1500 8 (10.5)
> 1,500 7 (9.2)
Serum Beta hCG on the 1st 
visit
< 15 iu 20 (26.3)
< 500 iu 45 (59.2)
500 - < 1000 iu 11 (14.5)
Serum Beta hCG on 2nd 
visit
<15 iu 49 (64.5)
15 iu - < 200 iu 27 (35.5)
200 - < 500 iu 00 (0)
GS diameter on discharge < 3.5 cm 76 (100)
> 3.5 cm 00 (0)
GS diameter on the  1st 
visit
< 2 cm 76 (100)
> 2 cm 00 (0)
GS diameter on the 2nd  
visit
< 0.5 cm 63 (82.9)
0.5 - < 1 cm 13 (17.1)
Table 2. Details of the treatment and outcomes
The first post-treatment visit was after one week from 
discharge and the serum beta hCG levels were all below 
1,000 iu with most below 500 iu and the gestational sac 
(GS) diameter reduced by more than 50% of the pre-
treatment size. The second post-treatment visit a week 
later found serum beta hCG levels were below 200 iu for 
all patients. The GS had disappeared for most patients. 
See Table 2.
After 5 patients underwent surgical intervention, only 76 
patients remained on treatment and follow up. 
Discussion
The success of medical management of EP using MTX 
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detection of EP before tubal rupture gives the obstetrician 
an opportunity to give medical treatment a trial.  We 
recommend proper counselling of patients at high risk for 
EP to seek early ante-natal attention.
Finally, we recommend this medical approach to be carried 
out in settings ready for emergency surgical intervention 
and blood transfusion. All patients were placed on follow-
up.
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